8-K Announcements
6Material company update
Apr 28, 2026·SEC
Material company update
Feb 17, 2026·SEC
Material company update
Jan 12, 2026·SEC
NeoGenomics, Inc.(NEO)Earnings, Financials & Key Ratios
NEO•NASDAQ
Price updated Jun 11, 2026
AboutNeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.Show more
- Revenue$727M+10.1%
- EBITDA$2M+108.9%
- Net Income-$108M-37.2%
- EPS (Diluted)-4.20-35.5%
- Gross Margin38.85%-11.5%
- EBITDA Margin0.24%+108.1%
- Operating Margin-9.09%+34.8%
- Net Margin-14.85%-24.6%
- ROE-12.42%-45.5%
- ROIC-4.33%+26.3%
- Debt/Equity0.56-15.8%
- Interest Coverage-17.61-57.3%
NEO Key Insights
NeoGenomics, Inc. (NEO) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 10.4%
- ✓Trading at only 0.4x book value
✗Weaknesses
- ✗Negative free cash flow
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when NEO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NEO Price & Volume
NeoGenomics, Inc. (NEO) stock price & volume — 10-year historical chart
Loading chart...
NEO Growth Metrics
NeoGenomics, Inc. (NEO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years21.97%
5 Years10.35%
3 Years12.58%
TTM10.95%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-27.87%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-25.57%
Return on Capital
10 Years-3.09%
5 Years-7.2%
3 Years-6.01%
Last Year-5.07%
NEO Recent Earnings
NeoGenomics, Inc. (NEO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 5/12 qtrs (42%)
Q2 2026Latest
Apr 28, 2026EPS
$0.01
Est $0.01
+73.0%
Revenue
$187M
Est $185M
+1.2%
Q1 2026
Feb 17, 2026EPS
$0.06
Est $0.04
+50.0%
Revenue
$190M
Est $188M
+0.9%
Q4 2025
Oct 28, 2025EPS
$0.03
Est $0.02
+50.0%
Revenue
$188M
Est $188M
-0.2%
Q3 2025
Jul 29, 2025EPS
$0.03
Est $0.03
+0.0%
Revenue
$181M
Est $184M
-1.4%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 28, 2026 | $0.01vs $0.01+73.0% | $187Mvs $185M+1.2% |
| Q1 2026 | Feb 17, 2026 | $0.06vs $0.04+50.0% | $190Mvs $188M+0.9% |
| Q4 2025 | Oct 28, 2025 | $0.03vs $0.02+50.0% | $188Mvs $188M-0.2% |
| Q3 2025 | Jul 29, 2025 | $0.03vs $0.03+0.0% | $181Mvs $184M-1.4% |
Based on last 12 quarters of dataView full earnings history →
NEO Peer Comparison
NeoGenomics, Inc. (NEO) competitors in Clinical and Specialty Lab Testing — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SLNO | 2.76B | 53.01 | 135.92 | 33.7% | 22.86% | 0.01 | ||
 CDNA | 1.22B | 23.66 | -59.15 | 13.79% | -1.98% | -2.61% | 0.06 | |
 NTRA | 31.4B | 219.23 | -144.23 | 35.9% | -9.05% | -15.13% | 0.13 | |
 EXAS | 20.02B | 104.91 | -95.37 | 17.69% | -6.4% | -8.66% | 1.05 | |
 LH | 21.83B | 265.27 | 25.36 | 7.25% | 6.66% | 10.89% | 0.83 | |
 DGX | 22.56B | 203.83 | 23.29 | 11.78% | 9.08% | 13.8% | 0.95 | |
 MYRG | 6.62B | 425.08 | 56.45 | 8.79% | 3.71% | 22.14% | 0.16 | |
 FLGT | 558.66M | 18.78 | -9.53 | 13.83% | -18.75% | -5.42% | 0.00 |
Compare NEO vs Peers
NeoGenomics, Inc. (NEO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NEO Income Statement
NeoGenomics, Inc. (NEO) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 240.25M | 276.74M | 408.83M | 444.45M | 484.33M | 509.73M | 591.64M | 660.57M | 727.33M | 745.97M |
Revenue Growth % | -1.57% | 15.19% | 47.73% | 8.71% | 8.97% | 5.24% | 16.07% | 11.65% | 10.11% | 10.95% |
Cost of Goods Sold | 138.29M | 149.48M | 211.99M | 258.56M | 297.27M | 321.83M | 347.04M | 370.47M | 444.79M | 431.69M |
COGS % of Revenue | 57.56% | 54.01% | 51.85% | 58.17% | 61.38% | 63.14% | 58.66% | 56.08% | 61.15% | - |
Gross Profit | 101.96M▲ 0% | 127.27M▲ 24.8% | 196.84M▲ 54.7% | 185.89M▼ 5.6% | 187.06M▲ 0.6% | 187.9M▲ 0.4% | 244.6M▲ 30.2% | 290.1M▲ 18.6% | 282.54M▼ 2.6% | 314.28M▲ 0% |
Gross Margin % | 42.44% | 45.99% | 48.15% | 41.83% | 38.62% | 36.86% | 41.34% | 43.92% | 38.85% | 42.13% |
Gross Profit Growth % | -7.63% | 24.82% | 54.67% | -5.56% | 0.63% | 0.45% | 30.18% | 18.6% | -2.61% | - |
Operating Expenses | 99.05M | 117.22M | 183.83M | 199.88M | 305.81M | 345.52M | 352.34M | 382.21M | 348.62M | 418.3M |
OpEx % of Revenue | 41.23% | 42.36% | 44.96% | 44.97% | 63.14% | 67.78% | 59.55% | 57.86% | 47.93% | - |
Selling, General & Admin | 113.3M | 114.22M | 175.34M | 191.66M | 283.94M | 277.91M | 279.96M | 310.49M | 365.34M | 364.02M |
SG&A % of Revenue | 47.16% | 41.27% | 42.89% | 43.12% | 58.63% | 54.52% | 47.32% | 47% | 50.23% | - |
Research & Development | 3.64M | 3M | 8.49M | 8.23M | 21.87M | 30.33M | 27.31M | 31.16M | 37.08M | 36.43M |
R&D % of Revenue | 1.51% | 1.08% | 2.08% | 1.85% | 4.52% | 5.95% | 4.62% | 4.72% | 5.1% | - |
Other Operating Expenses | 1.06M | 14K | 0 | 0 | 0 | 37.29M | 45.07M | 40.55M | -53.8M | 1000K |
Operating Income | 2.9M▲ 0% | 10.04M▲ 246.0% | 13.01M▲ 29.5% | -13.99M▼ 207.6% | -118.75M▼ 748.7% | -157.62M▼ 32.7% | -107.74M▲ 31.6% | -92.11M▲ 14.5% | -66.08M▲ 28.3% | -104.02M▲ 0% |
Operating Margin % | 1.21% | 3.63% | 3.18% | -3.15% | -24.52% | -30.92% | -18.21% | -13.94% | -9.09% | -13.94% |
Operating Income Growth % | 12.74% | 245.97% | 29.54% | -207.58% | -748.73% | -32.73% | 31.65% | 14.51% | 28.26% | - |
EBITDA | 25.49M | 31.77M | 43.28M | 27.9M | -65.4M | -88.19M | -35.15M | -19.56M | 1.75M | -53.93M |
EBITDA Margin % | 10.61% | 11.48% | 10.59% | 6.28% | -13.5% | -17.3% | -5.94% | -2.96% | 0.24% | -7.23% |
EBITDA Growth % | -1.12% | 24.63% | 36.21% | -35.54% | -334.44% | -34.85% | 60.14% | 44.36% | 108.92% | -210.72% |
D&A (Non-Cash Add-back) | 22.59M | 21.73M | 30.27M | 41.89M | 53.35M | 69.43M | 72.58M | 72.55M | 67.82M | 50.1M |
EBIT | 3.96M | 10.04M | 7.36M | -7.04M | -118.75M | -151.76M | -90.19M | -74.06M | -66.08M | -82.41M |
Net Interest Income | -5.54M | -6.23M | -3.71M | -7.02M | -5.08M | -1.51M | 9.99M | 11.81M | 5.32M | 3.21M |
Interest Income | 0 | 0 | 0 | 0 | 3.14M | 6.08M | 16.9M | 18.43M | 9.07M | 4.08M |
Interest Expense | 5.54M | 6.23M | 3.71M | 7.02M | 8.22M | 7.58M | 6.91M | 6.62M | 3.75M | 2.73M |
Other Income/Expense | -5.55M | -6.22M | -9.36M | -64K | 103.68M | -1.72M | 10.64M | 11.43M | -44.19M | 1.83M |
Pretax Income | -2.65M▲ 0% | 3.82M▲ 244.3% | 3.65M▼ 4.7% | -14.06M▼ 485.6% | -15.07M▼ 7.2% | -159.34M▼ 957.0% | -97.1M▲ 39.1% | -80.67M▲ 16.9% | -110.27M▼ 36.7% | -102.19M▲ 0% |
Pretax Margin % | -1.1% | 1.38% | 0.89% | -3.16% | -3.11% | -31.26% | -16.41% | -12.21% | -15.16% | -13.7% |
Income Tax | -2.25M | 1.18M | -4.36M | -18.23M | -6.73M | -15.09M | -9.13M | -1.95M | -2.24M | -2.98M |
Effective Tax Rate % | 85.06% | 30.96% | -119.64% | 129.68% | 44.63% | 9.47% | 9.4% | 2.42% | 2.03% | 2.92% |
Net Income | -396K▲ 0% | 2.64M▲ 766.7% | 8.01M▲ 203.3% | 4.17M▼ 47.9% | -8.35M▼ 300.1% | -144.25M▼ 1628.2% | -87.97M▲ 39.0% | -78.73M▲ 10.5% | -108.03M▼ 37.2% | -99.21M▲ 0% |
Net Margin % | -0.16% | 0.95% | 1.96% | 0.94% | -1.72% | -28.3% | -14.87% | -11.92% | -14.85% | -13.3% |
Net Income Growth % | 93.55% | 766.67% | 203.26% | -47.89% | -300.07% | -1628.17% | 39.02% | 10.51% | -37.22% | -27.87% |
Net Income (Continuing) | -396K | 2.64M | 8.01M | 4.17M | -8.35M | -144.25M | -87.97M | -78.73M | -108.03M | -99.21M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.03▲ 0% | 0.14▲ 660.0% | 0.39▲ 178.6% | 0.19▼ 51.3% | -0.35▼ 284.2% | -5.80▼ 1557.1% | -3.50▲ 39.7% | -3.10▲ 11.4% | -4.20▼ 35.5% | -3.84▲ 0% |
EPS Growth % | 93.75% | 660% | 178.57% | -51.28% | -284.21% | -1557.14% | 39.66% | 11.43% | -35.48% | -25.57% |
EPS (Basic) | -0.03 | 0.14 | 0.40 | 0.19 | -0.35 | -5.80 | -3.50 | -3.10 | -4.20 | - |
Diluted Shares Outstanding | 15.89M | 18.31M | 20.72M | 22.36M | 23.99M | 24.84M | 25.1M | 25.33M | 25.62M | 25.83M |
Basic Shares Outstanding | 15.89M | 18.31M | 20.09M | 21.72M | 23.99M | 24.84M | 25.1M | 25.33M | 25.62M | 25.83M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
NEO Balance Sheet
NeoGenomics, Inc. (NEO) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 84.96M | 103.67M | 290.74M | 448.73M | 681.51M | 605.29M | 596.81M | 596.02M | 376.29M | 373.68M |
Cash & Short-Term Investments | 12.82M | 9.81M | 173.02M | 296.26M | 515.39M | 437.99M | 415.2M | 386.84M | 159.62M | 146.14M |
Cash Only | 12.82M | 9.81M | 173.02M | 228.71M | 316.83M | 263.18M | 342.49M | 367.01M | 159.62M | 146.14M |
Short-Term Investments | 0 | 0 | 0 | 67.55M | 198.56M | 174.81M | 72.72M | 19.83M | 0 | 0 |
Accounts Receivable | 60.43M | 76.92M | 95.24M | 106.84M | 112.13M | 119.71M | 131.26M | 150.54M | 159.24M | 167.42M |
Days Sales Outstanding | 91.8 | 101.45 | 85.03 | 87.74 | 84.5 | 85.72 | 80.98 | 83.18 | 79.91 | 77.81 |
Inventory | 7.47M | 8.65M | 14.4M | 29.53M | 23.39M | 24.28M | 24.16M | 26.75M | 28.57M | 29.84M |
Days Inventory Outstanding | 19.73 | 21.12 | 24.8 | 41.68 | 28.73 | 27.53 | 25.41 | 26.35 | 23.44 | 25.58 |
Other Current Assets | 1M | 561K | 1.75M | 4.55M | 18.24M | 8.08M | 8.2M | 11.72M | 28.86M | 6.61M |
Total Non-Current Assets | 258.38M | 401.35M | 418.77M | 539.6M | 1.19B | 1.13B | 1.08B | 1.04B | 983.54M | 972.85M |
Property, Plant & Equipment | 36.5M | 60.89M | 90.68M | 151.89M | 211.66M | 198.61M | 183.78M | 173.69M | 163.28M | 160.36M |
Fixed Asset Turnover | 6.58x | 4.55x | 4.51x | 2.93x | 2.29x | 2.57x | 3.22x | 3.80x | 4.45x | 4.54x |
Goodwill | 147.02M | 197.89M | 198.6M | 211.08M | 527.12M | 522.77M | 522.77M | 522.77M | 524.34M | 524M |
Intangible Assets | 74.17M | 140.03M | 126.64M | 120.65M | 442.32M | 408.26M | 373.13M | 339.68M | 286.53M | 278.89M |
Long-Term Investments | -6.31M | -22.46M | 153K | 29.55M | 236K | 31K | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 689K | 2.54M | 2.69M | 21.01M | -48.54M | -29.67M | 4.74M | 5.89M | 9.39M | 9.6M |
Total Assets | 343.34M▲ 0% | 505.01M▲ 47.1% | 709.51M▲ 40.5% | 988.33M▲ 39.3% | 1.87B▲ 89.2% | 1.74B▼ 6.9% | 1.68B▼ 3.4% | 1.64B▼ 2.6% | 1.36B▼ 17.0% | 1.35B▲ 0% |
Asset Turnover | 0.70x | 0.55x | 0.58x | 0.45x | 0.26x | 0.29x | 0.35x | 0.40x | 0.53x | 0.54x |
Asset Growth % | 1.85% | 47.09% | 40.49% | 39.3% | 89.19% | -6.94% | -3.38% | -2.57% | -16.98% | -64.3% |
Total Current Liabilities | 35.06M | 60.92M | 63.9M | 73.18M | 87.23M | 89.93M | 96.3M | 301.24M | 88.3M | 84.59M |
Accounts Payable | 10.45M | 17.78M | 19.57M | 24.96M | 17.92M | 20.51M | 20.33M | 21.61M | 23.09M | 25.9M |
Days Payables Outstanding | 27.58 | 43.41 | 33.69 | 35.24 | 22 | 23.26 | 21.39 | 21.29 | 18.95 | 20.95 |
Short-Term Debt | 3.8M | 14.17M | 13.81M | 2.84M | 1.14M | 0 | 0 | 200.78M | 4.78M | 0 |
Deferred Revenue (Current) | -15.63M | 927K | 1.61M | 4.03M | 5.19M | 7.56M | 2.13M | 409K | 0 | 3.22M |
Other Current Liabilities | 1.41M | 2.69M | 7.55M | 0 | 16.66M | 15.07M | 53.16M | 75.07M | 60.43M | 40.58M |
Current Ratio | 2.42x | 1.70x | 4.55x | 6.13x | 7.81x | 6.73x | 6.20x | 1.98x | 4.26x | 4.42x |
Quick Ratio | 2.21x | 1.56x | 4.32x | 5.73x | 7.54x | 6.46x | 5.95x | 1.89x | 3.94x | 4.06x |
Cash Conversion Cycle | 83.95 | 79.16 | 76.14 | 94.18 | 91.22 | 89.99 | 85 | 88.25 | 84.41 | 82.45 |
Total Non-Current Liabilities | 102.74M | 123.65M | 138.19M | 220.85M | 674.27M | 652.08M | 643.39M | 434.46M | 434.97M | 433.18M |
Long-Term Debt | 91.15M | 98.13M | 91.83M | 168.12M | 532.48M | 535.32M | 538.2M | 340.33M | 404.68M | 342.24M |
Capital Lease Obligations | 5.28M | 0 | 27.23M | 43.26M | 72.29M | 68.95M | 67.87M | 60.84M | 62.82M | 255.22M |
Deferred Tax Liabilities | 6.31M | 22.46M | 15.57M | 5.42M | 55.48M | 34.75M | 24.29M | 21.51M | 18.22M | 76.49M |
Other Non-Current Liabilities | 6.97M | 3.06M | 2.4M | 3.34M | 13.03M | 13.05M | 13.03M | 11.77M | -51.14M | 12.03M |
Total Liabilities | 137.81M | 184.57M | 202.1M | 294.04M | 761.5M | 742.01M | 739.69M | 735.7M | 523.27M | 517.77M |
Total Debt | 105.42M | 112.3M | 132.88M | 218.22M | 612.79M | 610.93M | 611.68M | 605.33M | 472.28M | 408.53M |
Net Debt | 92.6M | 102.49M | -40.14M | -10.49M | 295.96M | 347.75M | 269.19M | 238.32M | 312.66M | 262.39M |
Debt / Equity | 0.51x | 0.35x | 0.26x | 0.31x | 0.55x | 0.61x | 0.65x | 0.67x | 0.56x | 0.49x |
Debt / EBITDA | 4.14x | 3.53x | 3.07x | 7.82x | - | - | - | - | 270.65x | -7.58x |
Net Debt / EBITDA | 3.63x | 3.23x | -0.93x | -0.38x | - | - | - | - | 179.17x | -4.87x |
Interest Coverage | 0.71x | 1.61x | 1.98x | -1.00x | -14.45x | -20.02x | -13.06x | -11.19x | -17.61x | -30.15x |
Total Equity | 205.53M▲ 0% | 320.44M▲ 55.9% | 507.41M▲ 58.3% | 694.29M▲ 36.8% | 1.11B▲ 59.6% | 998.02M▼ 9.9% | 941.54M▼ 5.7% | 902.34M▼ 4.2% | 836.56M▼ 7.3% | 828.76M▲ 0% |
Equity Growth % | 10.15% | 55.91% | 58.35% | 36.83% | 59.63% | -9.95% | -5.66% | -4.16% | -7.29% | -28.44% |
Book Value per Share | 12.94 | 17.50 | 24.49 | 31.05 | 46.19 | 40.17 | 37.51 | 35.62 | 32.65 | 32.08 |
Total Shareholders' Equity | 205.53M | 320.44M | 507.41M | 694.29M | 1.11B | 998.02M | 941.54M | 902.34M | 836.56M | 828.76M |
Common Stock | 80K | 94K | 105K | 112K | 124K | 127K | 127K | 128K | 129K | 129K |
Retained Earnings | -57.47M | -51.26M | -11.36M | -7.18M | -14.84M | -159.09M | -247.06M | -325.78M | -433.81M | -450.91M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 274K | -579K | -1.62M | 10K | -638K | -3.9M | -1.67M | -206K | 4K | 4K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NEO Cash Flow Statement
NeoGenomics, Inc. (NEO) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 18.04M | 44.79M | 23.37M | 1.46M | -26.72M | -65.99M | -1.95M | 7.02M | 5.23M | 22.42M |
Operating CF Margin % | 7.51% | 16.18% | 5.72% | 0.33% | -5.52% | -12.95% | -0.33% | 1.06% | 0.72% | - |
Operating CF Growth % | -16.02% | 148.3% | -47.82% | -93.75% | -1930.34% | -146.95% | 97.04% | 459.6% | -25.53% | 24% |
Net Income | -846K | 2.64M | 8.01M | 4.17M | -8.35M | -144.25M | -87.97M | -78.73M | -108.03M | -99.21M |
Depreciation & Amortization | 22.59M | 21.73M | 30.27M | 35.72M | 53.35M | 69.43M | 72.58M | 72.55M | 67.82M | 66.51M |
Stock-Based Compensation | 6.44M | 6.96M | 10M | 10.21M | 22.46M | 24.67M | 24.63M | 33.41M | 41.32M | 32.16M |
Deferred Taxes | 19.96M | 404K | 1.49M | 951K | 0 | -16.1M | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 440K | 542K | 6.03M | 12.15M | -89.59M | 31.95M | 14.29M | 12.42M | 36.21M | 24.82M |
Working Capital Changes | -30.55M | 12.51M | -32.42M | -61.75M | -4.6M | -31.7M | -25.49M | -32.63M | -32.09M | -1.85M |
Change in Receivables | -24.24M | 209K | -17.3M | -12.6M | -4.69M | -7.58M | -11.52M | -19.31M | -6.18M | -13.69M |
Change in Inventory | -1.42M | 734K | -5.75M | -15.2M | 1.63M | -1.1M | -454K | -2.7M | -1.54M | 210K |
Change in Payables | -4.54M | 12.92M | -9M | -3.97M | 19.32M | 2.79M | -4.55M | -4M | -4.69M | -5.12M |
Cash from Investing | -13.69M | -139.69M | -19.63M | -159.44M | -632.37M | 517K | 76.71M | 12.86M | -12.34M | -20.9M |
Capital Expenditures | -13.69M | -14.31M | -20.03M | -29.1M | -64.14M | -30.89M | -28.75M | -41.06M | -27.01M | -27.51M |
CapEx % of Revenue | 5.7% | 5.17% | 4.9% | 6.55% | 13.24% | 6.06% | 4.86% | 6.22% | 3.71% | 3.69% |
Acquisitions | 0 | -125.38M | 399K | -37M | -419.4M | 0 | 0 | 0 | -6.45M | -6.45M |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | -15M | 12.1M | 0 | 0 | 1.57M | 1.57M |
Cash from Financing | -4.09M | 91.96M | 159.47M | 235.6M | 725.28M | 11.83M | 4.55M | 4.65M | -200.29M | -201.57M |
Debt Issued (Net) | -6.68M | 5.1M | -12.51M | 91.31M | 334.41M | -758K | -70K | 0 | -201.25M | -201.25M |
Equity Issued (Net) | 2.59M | 94M | 171.98M | 147.6M | 423.21M | 12.59M | 4.62M | 4.65M | 962K | 13K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | -50.1M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | -7.14M | 0 | -3.32M | -32.34M | 0 | 0 | 0 | 0 | -338K |
Net Change in Cash | 296K▲ 0% | -3.01M▼ 1116.9% | 163.21M▲ 5522.1% | 77.62M▼ 52.4% | 66.19M▼ 14.7% | -53.65M▼ 181.0% | 79.31M▲ 247.8% | 24.52M▼ 69.1% | -207.39M▼ 945.7% | -200.05M▲ 0% |
Free Cash Flow | 4.35M▲ 0% | 30.48M▲ 601.1% | 3.34M▼ 89.0% | -27.64M▼ 927.4% | -90.86M▼ 228.8% | -96.88M▼ 6.6% | -30.7M▲ 68.3% | -34.04M▼ 10.9% | -21.78M▲ 36.0% | -5.09M▲ 0% |
FCF Margin % | 1.81% | 11.01% | 0.82% | -6.22% | -18.76% | -19.01% | -5.19% | -5.15% | -2.99% | -0.68% |
FCF Growth % | -68.82% | 601.08% | -89.04% | -927.43% | -228.79% | -6.62% | 68.31% | -10.85% | 36.02% | 84.28% |
FCF per Share | 0.27 | 1.66 | 0.16 | -1.24 | -3.79 | -3.90 | -1.22 | -1.34 | -0.85 | -0.20 |
FCF Conversion (FCF/Net Income) | -45.55x | 16.96x | 2.92x | 0.35x | 3.20x | 0.46x | 0.02x | -0.09x | -0.05x | 0.05x |
Interest Paid | 5.16M | 0 | 4.78M | 2.93M | 3.06M | 3.4M | 3.38M | 3.83M | 0 | 1.69M |
Taxes Paid | 284K | 0 | 319K | 246K | 148K | 180K | 175K | 207K | 0 | 458K |
NEO Key Ratios
NeoGenomics, Inc. (NEO) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -0.2% | 1% | 1.93% | 0.69% | -0.93% | -13.7% | -9.07% | -8.54% | -12.42% | -11.82% |
| Return on Invested Capital (ROIC) | 0.75% | 2.09% | 2.19% | -1.82% | -8.53% | -8.6% | -6.32% | -5.88% | -4.33% | -7.04% |
| Gross Margin | 42.44% | 45.99% | 48.15% | 41.83% | 38.62% | 36.86% | 41.34% | 43.92% | 38.85% | 42.13% |
| Net Margin | -0.16% | 0.95% | 1.96% | 0.94% | -1.72% | -28.3% | -14.87% | -11.92% | -14.85% | -13.3% |
| Debt / Equity | 0.51x | 0.35x | 0.26x | 0.31x | 0.55x | 0.61x | 0.65x | 0.67x | 0.56x | 0.49x |
| Interest Coverage | 0.71x | 1.61x | 1.98x | -1.00x | -14.45x | -20.02x | -13.06x | -11.19x | -17.61x | -30.15x |
| FCF Conversion | -45.55x | 16.96x | 2.92x | 0.35x | 3.20x | 0.46x | 0.02x | -0.09x | -0.05x | 0.05x |
| Revenue Growth | -1.57% | 15.19% | 47.73% | 8.71% | 8.97% | 5.24% | 16.07% | 11.65% | 10.11% | 10.95% |
Related:NEO Dividend History·NEO Revenue History·NEO Price History·NEO P/E History·NEO Financial Ratios·NEO Institutional Holders
NEO SEC Filings & Documents
NeoGenomics, Inc. (NEO) SEC filings — annual & quarterly reports (10-K, 10-Q)
NEO Frequently Asked Questions
NeoGenomics, Inc. (NEO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
NeoGenomics, Inc. (NEO) reported $746.0M in revenue for fiscal year 2025. This represents a 295447% increase from $0.3M in 2000.
NeoGenomics, Inc. (NEO) grew revenue by 10.1% over the past year. This is steady growth.
NeoGenomics, Inc. (NEO) reported a net loss of $99.2M for fiscal year 2025.
Dividend & Returns
NeoGenomics, Inc. (NEO) has a return on equity (ROE) of -12.4%. Negative ROE indicates the company is unprofitable.
NeoGenomics, Inc. (NEO) had negative free cash flow of $5.1M in fiscal year 2025, likely due to heavy capital investments.